KALY – Kali-Extracts Continues Cannabinoid Testing For CBD Extraction Contract Worth Anticipated $5 Million
KALY has entered into a contract to extract CBD from a hemp crop managed by a licensed hemp grower in the State of New York.
Read More
Category: Biomedical
Axim® Biotechnologies Begins Manufacturing Cannabinoid-Based Gum With Dronabinol for Use in Upcoming Pre-Clinical Studies
The clinical studies will involve the use of cannabis as a treatment for chemotherapy related symptoms.
Read More
Autism Spectrum Disorder, Fragile X Syndrome, and 22q11.2 Deletion Syndrome Share a Constellation of Sociobehavioral Symptoms
Preliminary Evidence Shows that CBD May Prove to be Effective in Managing the Spectrum of Behavioral Symptoms Associated with these Conditions.
Read More
New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)
Ninety Percent of Interviewed Caregivers Reported Social Avoidant, Irritability, and Socially Lethargic Behaviors in their Children with FXS.
Read More
KALY – Kali-Extracts Confirms Cannabinoid Testing For $5 Million Hemp Extraction Contract
KALY has entered into a contract to extract CBD from a hemp crop managed by a licensed hemp grower in the State of New York.
Read MoreGET LISTED
